Breaking News
November 19, 2017 - Dental filling failure linked to smoking, drinking and genetics
November 19, 2017 - Medicaid expansion takes a bite out of medical debt
November 19, 2017 - Study aims to involve parents in early intervention services for children with autism
November 19, 2017 - Don’t Fret Delays in Treating Colon Cancer, Study Suggests
November 19, 2017 - Yeast Infection Test: MedlinePlus Lab Test Information
November 19, 2017 - Video of blood clot contraction reveals how platelets naturally form unobtrusive clots
November 19, 2017 - UNN researchers explore modeling of cognitive dissonance phenomenon
November 19, 2017 - Verseon presents second anticoagulation candidate for clinical trials at AHA 2017
November 19, 2017 - Pregnant Asian women who develop high blood pressure at highest risk for heart failure hospitalization
November 19, 2017 - Medicare seeks comment on ways to cut costs of Part D drugs
November 19, 2017 - Tree cover linked to fewer asthma cases in polluted urban neighborhoods
November 19, 2017 - Make the Diagnosis: Hair Care Conundrum
November 19, 2017 - New techniques give blood biopsies greater promise
November 19, 2017 - Researchers identify possible genetic basis for coronary artery disease
November 19, 2017 - Stress experienced by emergency call handlers has negative impact on psychological health
November 18, 2017 - New cancer cell screening is improving childhood leukaemia treatment
November 18, 2017 - Groundbreaking study identifies protein as potential factor in cancer metastasis
November 18, 2017 - New model to test effectiveness of existing and potential CF therapies
November 18, 2017 - Staying Active May Lower Odds for Glaucoma
November 18, 2017 - Potential new autism drug shows promise in mice
November 18, 2017 - Some states roll back ‘retroactive Medicaid,’ a buffer for the poor — and for hospitals
November 18, 2017 - Selectively deleting stem cell factor promotes recovery after TBI in mice
November 18, 2017 - Breakthrough research brings new procedure closer to helping patients with blood cancer
November 18, 2017 - Dr Peter Simpson Appointed to SLAS Board of Directors
November 18, 2017 - Friendships between young children can protect against ADHD
November 18, 2017 - Old World monkeys could hold key to stop progression of rheumatoid arthritis
November 18, 2017 - Harris Health System RNs named among 20 Outstanding Nurses for 2017
November 18, 2017 - Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy
November 18, 2017 - Mount Sinai researchers identify new therapeutic target for ER+ breast cancer
November 18, 2017 - Age, CRP levels predict success in tapering of biologics in rheumatoid arthritis patients
November 18, 2017 - New dye could be used to observe electrical activity of neurons in the brain
November 18, 2017 - New study further validates use of vaginal progesterone to decrease risk of preterm birth
November 18, 2017 - Russian researcher determined range of reference values for boron in the human body
November 18, 2017 - ‘What the Health?’ Tax bill or health bill?
November 18, 2017 - Could Your Cat Give You ‘Bird Flu?’
November 18, 2017 - Vitamin D Linked to Fertility Outcomes in ART
November 18, 2017 - Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer’s disease
November 18, 2017 - Tax reform proposal could impact care for older Americans
November 18, 2017 - PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease
November 18, 2017 - Researchers receive £1.3 million to develop sight-saving imaging technology
November 18, 2017 - Novel buckypaper sensor could pave way for high-performance, affordable wearable technology
November 18, 2017 - Despite ACA cost protections, most adolescents skip regular checkups
November 18, 2017 - Stem cell treatment allows paraplegic rats to walk and regain sensory perception
November 18, 2017 - HTC analytical conference comes to the UK
November 18, 2017 - Face It: Drinking, Smoking Takes Toll on Looks: MedlinePlus Health News
November 18, 2017 - New research shows where in the brain the earliest signs of Alzheimer’s occur
November 18, 2017 - Philips announces launch of global movement to raise awareness for COPD
November 18, 2017 - University of Bristol awarded grant to reduce antibacterial drug resistance in Thailand
November 18, 2017 - New oxytocin chemical sensor could be first step towards early diagnosis of autism
November 18, 2017 - Study shows how naïve T-cells may affect tumor immunity and immunotherapy
November 18, 2017 - New studies highlight importance of cardiorespiratory fitness to reduce CVD risk
November 18, 2017 - Study finds medical cannabis is effective at reducing opioid addiction
November 18, 2017 - Specially tailored, ultrafast light pulses can trigger neurons to fire in different patterns
November 18, 2017 - Decrease in sunshine linked to rising incidence of Rickets
November 18, 2017 - Harnessing social media big data to fight against prescription drug crisis
November 18, 2017 - Researchers find way to switch tumor cells between 2D and 3D morphology
November 18, 2017 - Leaf-eating ability of beetle largely due to bacteria inside the insect
November 18, 2017 - FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors
November 18, 2017 - Adolescents underreport amphetamine use, likely unaware that adderall is amphetamine
November 18, 2017 - Study reveals a reduced risk of teenage eczema in breastfed babies
November 18, 2017 - Separating side effects could pave way for safe, effective pain medications
November 18, 2017 - Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
November 18, 2017 - Environmental triggers may play role in development of Lupus
November 18, 2017 - Review looks into conventional versus new treatment modalities in orthodontic pain management
November 17, 2017 - FDA Alert: Diphenoxylate Hydrochloride and Atropine Sulfate Tablets by Greenstone: Recall
November 17, 2017 - For older women, every movement matters
November 17, 2017 - Talking-based therapy could transform aftercare for cancer survivors
November 17, 2017 - Olympus IXplore SpinSR10 imaging system enables researchers to observe fine details in live cells
November 17, 2017 - Study explores reasons for underrepresentation of minorities in genetic cancer research
November 17, 2017 - California firm running physician practices is closing down as scrutiny ramps up
November 17, 2017 - BMI not valid measure of obesity in postmenopausal women, study shows
November 17, 2017 - Vaginal progesterone decreases the risk of premature birth in women with short cervix
November 17, 2017 - Pricey ER Tests for Chest Pain Often Unnecessary
November 17, 2017 - ‘Old’ Lungs May Be Good Transplant Options: MedlinePlus Health News
November 17, 2017 - How not to gain weight over the holidays
November 17, 2017 - Researchers map first-ever proteome of healthy human heart
November 17, 2017 - Drug used to prevent and treat malaria may also be effective for Zika virus
November 17, 2017 - One in 20 children still receiving codeine to treat pain despite warning from federal regulators
November 17, 2017 - Improving clinical trials with machine learning
November 17, 2017 - Experts identify mental exercise program that can reduce risk of dementia
Tocilizumab Benefits Persist in SSc

Tocilizumab Benefits Persist in SSc

image_pdfDownload PDFimage_print

Action Points

  • Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial.
  • The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis.

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

At week 48, the conclusion of the double-blind phase of a study known as faSScinate, change from baseline on the modified Rodnan skin score was -5.6 (95% CI -8.9 to -2.4) among patients who were receiving tocilizumab, according to Dinesh Khanna, MD, of the University of Michigan in Ann Arbor, and colleagues.

By week 96, additional decreases were seen on skin scores, bringing the total improvement to a score of -9.1 (95% CI -12.5 to -5.6).

Meanwhile, patients who had been randomized to placebo for the first 48 weeks had a change from baseline in Rodnan skin scores of -3.1 (95% CI -5.4 to -0.9), but by week 96, after 48 weeks of open-label tocilizumab, mean change in score was -9.4 (95% CI -11.8 to -7), the investigators reported online in Annals of the Rheumatic Diseases.

The differences at week 48, while clinically meaningful, were not statistically significant, they noted.

Morbidity and mortality are high among patients with systemic sclerosis, particularly among those with lung involvement, and few treatment options are available. Cyclophosphamide has been used for pulmonary disease, but is associated with significant toxicity, and stem cell transplantation has improved skin fibrosis and lung function but is associated with risks and high costs.

The rationale for using tocilizumab, a monoclonal antibody targeting the interleukin (IL)-6 receptor-α, is that IL-6 is thought to be involved in the pathogenesis of SSc, with patients having increased IL-6 expression in endothelial cells and elevations of IL-6 in serum.

The faSScinate study was conducted in 35 centers in North America and Europe, enrolling 87 patients with active disease of less than 5 years’ duration. The majority were white women, and baseline total modified Rodnan skin score was about 25. The treatment consisted of subcutaneous injections of tocilizumab, 162 mg, once weekly.

At week 48, 30 (69.8%) of the patients originally randomized to tocilizumab entered the open-label phase, as did 31 (70.5%) of those who received placebo in the blinded phase. The full 96-week study was completed by 27 (62.8%) of those who had been on active treatment throughout and by 24 (54.5%) of those originally given placebo.

By week 96, a total of 27 patients who had been on continuous tocilizumab (during the placebo-controlled phase and the open-label phase) had achieved the minimal clinically important difference on the skin score of a change of at least 4.7 units, as had 24 of those in the placebo-tocilizumab group.

For lung function, similar proportions of patients in the continuous tocilizumab and placebo-tocilizumab experienced absolute decreases in percent predicted forced vital capacity in the open-label phase (46% and 42%, respectively), whereas during the double-blind phase, 54% of the tocilizumab group experienced any worsening compared with 83% of those in the placebo group.

Improvements also were seen on patient-reported outcomes by week 96 for both continuous tocilizumab and placebo-tocilizumab groups. For instance, on the Health Assessment Questionnaire Disability Index, changes from baseline were -0.13 and -0.29, respectively.

The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis. However, “rates of serious adverse events and serious infections in this study in patients with SSc were approximately five times and eight times higher, respectively, than those reported in patients with rheumatoid arthritis, which is expected given the high morbidity and mortality in patients with SSc,” the authors wrote.

In particular, patients with SSc are prone to develop digital ulcers, and two patients had infected digital ulcers and one had osteomyelitis.

The investigators emphasized that the study was not powered for a statistical comparison of efficacy during the open-label phase, noting that a phase III randomized controlled trial (NCT02453256) including more than 200 patients is underway.

They concluded that tocilizumab was beneficial for skin and lung manifestations of SSc, and “may be a promising targeted therapy for patients with progressive SSc who have few treatment options.”

Limitations of the study were its open-label design after week 48 and a high discontinuation rate. In addition, patients who completed the 48-week blinded phase and entered the open-label phase may have been healthier, so selection bias was possible.

The study was funded by Roche.

The authors reported financial relationships with Roche, Actelion, Boehringer-Ingelheim, Covis, CSL Behring, Corbus, Cytori, EMD Serono, Genentech/Roche, GlaxoSmithKline, Inventiva, Medac, Sanofi-Aventis, UCB, Bristol-Myers Squibb, Bayer, Pfizer, Eicos Sciences, AstraZeneca, Eli Lilly, Galapagos, Servier, Sandoz, and Chugai. Several are employees of Roche or Genentech.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-10-25T14:30:00-0400

Tagged with:

About author

Related Articles